PMID: 25764674Mar 15, 2015Paper

JSH guidelines for the management of hepatitis C virus infection (version 3)

Nihon rinsho. Japanese journal of clinical medicine
Atsushi Tanaka

Abstract

Recently, the management of chronic hepatitis C virus (HCV) has been greatly advanced with introduction of direct acting antivirals (DAAs) in clinical setting. The Japan Society of Hepatology (JSH) first released the clinical practice guideline for the management of HCV infection in 2012, and revised in 2013 along with the introduction of a second-generation DAA, simeprevir (SMV). In September 2014, the first IFN-free DAAs, daclatasvir (DCV) and asunaprevir (ASV), were launched and the antiviral therapy for IFN intolerant/ineligible patients became to be possible. Thence the society has now revised the clinical practice guidelines at this time, and added a new treatment flow-chart for the antiviral therapy in patients with cirrhosis. In this article I summarized the revised guidelines and would like to introduce the treatment recommendations.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Current Opinion in Gastroenterology
Mitchell L Shiffman
Hepatology Research : the Official Journal of the Japan Society of Hepatology
Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
Hepatology Research : the Official Journal of the Japan Society of Hepatology
Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology
© 2021 Meta ULC. All rights reserved